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Introduction
The development of diabetic nephropathy (DN) is the leading
cause of end-stage renal disease and is clinically characterized by
proteinuria and progressive renal insufficiency [1]. It is postulated
that localized oxidative stress is a key component in the develop-
ment of DN [2] and accumulating evidence suggests, that patients
with diabetes mellitus have increased rates of lipoprotein oxidation
products [3, 4]. The pathogenic role of oxidized low-density
lipoprotein (oxLDL) in the kidney has been studied in vitro on a
variety of renal cells, like mesangial cells [5–7], endothelial cells
[8, 9] and podocytes [10]. Many important roles have been
ascribed to oxLDL, which could be involved in the progression of
renal diseases. It is well known that oxLDL can induce the produc-
tion of chemokines and the expression of adhesion molecules on
endothelial cells [11]. Furthermore, oxLDL can harm the kidney
either directly, by deposition of lipids, or indirectly, by stimulating
the generation of reactive oxygen species (ROS) [12, 13]. In addi-
tion to this in vitro data, several animal models have documented
that chronic exposure to oxLDL promotes collagen synthesis and
activates pro-inflammatory pathways [14, 15]. Moreover, oxLDL
also promotes fibrosis by stimulating synthesis and expression of
TGF- [16].
Beside the important role of mesangial cells in the onset of DN
[17], accumulating data demonstrate that podocytes are function-
ally and structurally injured very early in the natural history of DN
[18]. Therefore, in order to improve the treatment of glomerular
diseases like DN the identification of new proteins involved in
CXCL16 and oxLDL are induced in the onset of 
diabetic nephropathy
Paul Gutwein 
a, *, Mohamed Sadek Abdel-Bakky 
a, Kai Doberstein 
a, Anja Schramme 
b, 
Janet Beckmann 
a, Liliana Schaefer 
a, Kerstin Amann 
c, Anke Doller 
a, Nicole Kämpfer-Kolb 
a, 
Abdel-Aziz H. Abdel-Aziz 
d, El Sayed M. El Sayed 
d, Josef Pfeilschifter 
a
a pharmazentrum frankfurt/ZAFES, University Hospital, Goethe University Frankfurt, Frankfurt, Germany
b Institute of Reconstructive Neurobiology, Life & Brain Center, University of Bonn and Hertie Foundation, Bonn, Germany
c Department of Urology, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, Germany
d Department of Pharmacology and Toxicology, Faculty of Pharmacology, Al-Azhar University, Cairo, Egypt
Received: November 7, 2008; Accepted: March 10, 2009
Abstract
Diabetic nephropathy (DN) is a major cause of end-stage renal failure worldwide. Oxidative stress has been reported to be a major 
culprit of the disease and increased oxidized low density lipoprotein (oxLDL) immune complexes were found in patients with DN. In this
study we present evidence, that CXCL16 is the main receptor in human podocytes mediating the uptake of oxLDL. In contrast, in pri-
mary tubular cells CD36 was mainly involved in the uptake of oxLDL. We further demonstrate that oxLDL down-regulated 3-integrin
expression and increased the production of fibronectin in human podocytes. In addition, oxLDL uptake induced the production of reac-
tive oxygen species (ROS) in human podocytes. Inhibition of oxLDL uptake by CXCL16 blocking antibodies abrogated the fibronectin
and ROS production and restored 3 integrin expression in human podocytes. Furthermore we present evidence that hyperglycaemic
conditions increased CXCL16 and reduced ADAM10 expression in podocytes. Importantly, in streptozotocin-induced diabetic mice an
early induction of CXCL16 was accompanied by higher levels of oxLDL. Finally immunofluorescence analysis in biopsies of patients with
DN revealed increased glomerular CXCL16 expression, which was paralleled by high levels of oxLDL. In summary, regulation of CXCL16,
ADAM10 and oxLDL expression may be an early event in the onset of DN and therefore all three proteins may represent potential new
targets for diagnosis and therapeutic intervention in DN.
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podocyte injury are of high importance. The loss of podocytes,
also known as podocytopenia, is an important characteristic fea-
ture in diabetic patients [19–22] and beside pro-inflammatory
actions of oxLDL, the cytotoxic effects of oxLDL on podocytes has
been recently shown [10]. Scavenger receptors are found on
many cell lineages. They are known to bind modified lipoproteins
and to promote the transformation of macrophages (M) and
smooth muscle cells into foam cells [23, 24]. However, little is
known about the regulation and function of scavenger receptors in
normal and pathological states of the kidney.
CXCL16 (SR-PSOX) is one of the few scavenger receptors
that is found in two distinct forms: membrane bound and solu-
ble. Surface-expressed CXCL16 binds and internalizes oxLDL
and promotes adhesion of cells expressing its cognate receptor
CXCR6 [25, 26]. In contrast soluble CXCL16 produced by pro-
teolytic cleavage via ADAM10 and ADAM17 [27, 28], acts as a
chemotactic factor for CXCR6 expressing cells such as NKT and
polarized T helper cells [29, 30]. Importantly, in an animal
model of chronic kidney disease elevated CXCL16 levels were
accompanied with increased levels of oxLDL in the onset of
renal obstruction [31]. We have recently described the expres-
sion of CXCL16 and ADAM10 in human podocytes and pre-
sented evidence that CXCL16 is involved in the uptake of oxLDL
in human podocytes (Gutwein et al., unpublished results). In
this study we investigated the functional consequences of
CXCL16 mediated uptake of oxLDL in human podocytes.
Additionally we characterized CXCL16 and oxLDL expression in
kidney sections of streptozotocin- (STZ) induced diabetic mice.
Furthermore CXCL16, ADAM10 and oxLDL expression was




Specimens were taken from healthy parts of renal tissue from six differ-
ent tumour nephrectomies (obtained from two female and four male
patients with ages from 34 to 66 years), which were originally submitted
for diagnostic purposes and studied in accordance with national and
local ethical principles. The use of human tissue samples has been
approved by the local ethics committee (Ref-No. 11/10/04). Tissue sec-
tions of four patients diagnosed with DN were obtained from the
Department of Urology, Friedrich Alexander University of Erlangen-
Nuremberg, Erlangen, Germany. Patients’ characteristics are depicted in
Table 1. The investigations of human kidney biopsies were approved by
the local ethics committee.
Cell culture
Human conditionally immortalized podocytes were isolated and cultivated
as previously described [32]. Cells were grown in flasks either at the permissive
temperature of 32C (in 5% CO2) to promote cell propagation as a cobble-
stone phenotype (undifferentiated) or at the non-permissive temperature
of 37C (in 5% CO2) to inactivate the SV40 T antigen and to allow the cells
to differentiate. The growth medium was RPMI 1640 supplemented with
non-essential amino acids, foetal bovine serum (10%), Hepes (10 mM) pH
7.4, penicillin (100 U/ml), streptomycin (100 g/ml), transferrin (5 g/ml)
and sodium selenite (5 ng/ml). Prior to stimulation, cells were incubated
for 16 hrs in RPMI 1640 medium, supplemented with 0.1 mg/ml of fatty
acid-free bovine serum albumine.
Primary human renal cortical epithelial cells (HRCEpiC) were supplied
from Provitro (Berlin, Germany) and cultured according to the manufac-
turer’s instructions. HRCEpiC were grown at 37C and 5% CO2 and cul-
tured in epithelial cell medium which consisted of 500 ml of basal medium,
10 ml of foetal bovine serum (2%), 5 ml of epithelial cell growth supple-
ment and 5 ml of penicillin/streptomycin solution (media ingredients were
purchased from provitro).
Cytokines, chemicals and antibodies
The blocking anti-human CXCL16 antibody, recombinant human CXCL16,
recombinant human TGF- and the ADAM10 antibody used for immuno-
fluorescence staining were obtained from R&D Systems (Wiesbaden,
Germany). Unconjugated rabbit CXCL16 antibody used for immunohisto-
chemistry and immunofluorescence was from PeproTech EC, (London,
UK). DiI-oxLDL and oxLDL were purchased from Intracel (Frederick, MD,
USA). The blocking anti-CD36 antibody was from Abcam (Cambridge, UK).
The monoclonal mouse ADAM10 antibody used in immunofluorescence
analysis on tissue sections was from Diaclone (Cologne, Germany). Alexa
Fluor 594 phalloidin was purchased from Molecular Probes (Karlsruhe,
Germany). Polyclonal rabbit fibronectin antibody and monoclonal CD36
antibody used in immunofluorescense analysis was obtained from Santa
Cruz (Heidelberg, Germany). The 3-integrin, ADAM10 and oxLDL anti-
body were from Chemicon (Hampshire, UK). The 5-(and-6)-chloromethyl-
27-dichlorodihydro-fluoroscein diacetate was obtained from Invitrogen
(Karlsruhe, Germany).
siRNA
For down-regulation of endogenous ADAM10 expression in human
podocytes the following duplex (MWG Biotech AG, Ebersberg, Germany)
was used: ADAM10 construct, 5-AGA CAU UAU GAA GGA UUA UTT-3 As
a negative control an unspecific scrambled siRNA duplex (5-AGG UAG
UGU AAU CGC CUU GTT-3) was applied.
© 2009 The Authors







1 m 60 4 y 3 2.1 Mild
2 f 47 Short 5 3.4 Mild
3 m 68 Short 5 2.0 No
4 m 55 Short 4.57 3.5 Mild
Table 1 Clinicopathological data of patients analysed by immunofluo-
rescense on kidney biopsies (dm 	 diabetes mellitus, y 	 years, S-crea 	
serum creatinin, m 	 male, f 	 female)J. Cell. Mol. Med. Vol 13, No 9B, 2009
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Protein extraction and western blotting
Cell extracts were prepared 48 hrs after siRNA transfection. PVDF mem-
branes were incubated with antibodies against ADAM10 (Chemicon). Blots
were developed using the ECL system (AmershamPharmacia,
Buckingshamshire, UK). To confirm equal loading, blots were reprobed
with a -actin antibody (Sigma, Deisenhofen, Germany).
Real-time RT-PCR
One-step RT-PCR was performed with a Taqman (ABI 7000) from
PerkinElmer-Cetus (Waltham, MA, USA). The mRNA levels for CXCL-16
and -actin were determined by using a ‘hot start’ real-time PCR procedure
with Quanti-Tec SYBR Green (QIAGEN). The following oligonucleotides
were used as Taqman hybridization probes: CXCL-16 forward, 5-ACG-
GAGTCTCGCTCTGTCAT-3; CXCL-16 reverse, 5-TGGTGAAACCCCGTCTC-
TAC-3; -actin forward, 5-GGACTTCGAGCAAGAG-ATGG-3 and -actin
reverse, 5-AGCACTGTGTTGGCGTACAG-3. Calculation of relative CXCL-16
mRNA levels was done by using the 2 [-

C(T)] method [33]. According
to this method, the C(T) values of CXCL-16 mRNA level were normalized to
the C(T) values of -actin mRNA in the same sample.
ROS production assay
Human podocytes grown on cover slip were pre-incubated for 1 hr with or
without CXCL16 (10 g/ml) or CD36 (5 g/ml) blocking antibodies before
the cells were treated with oxLDL (100 g/ml) for 16 hrs. Cells were then
washed with Dulbecco’s PBS and incubated with media containing 5 mM
5-(and-6)-chloromethyl-27-dichlorodihydrofluoroscein diacetate acetyl
ester (CM-H2DCFDA) for 20 min. in the dark. Culture dishes were trans-
ferred to a digital microscope from Keyence (Neu-Isenburg, Germany) to
document and analyse ROS generation.
CXCL16 shedding assays
Twenty-four hours before incubation with low glucose (LG) (5 mM) or high
glucose (HG) (30 mM) containing media, podoctes were seeded at a den-
sity of 0.5  10
5 cells in six-well plates. Cells were washed with PBS and
1 ml of LG or HG containing media was added. The conditioned media were
harvested at 24, 72 and 120 hrs and cleared by centrifugation. The pres-
ence of soluble CXCL16 in the conditioned media was analysed by ELISA
(PeproTech) following the manufacturers instructions.
Immunofluorescence analysis of cells
Cells plated on cover slips were fixed with methanol/ 0.01% ethylenedi-
aminetetraacetic acid (EDTA) for 20 min. at –20C. After fixation, cells were
blocked for 15 min. at room temperature with 0.1% Triton X-100/ PBS con-
taining 5% bovine serum albumin (BSA), washed with PBS and incubated
overnight with the primary antibody (diluted in 5% BSA/PBS/0.1% Triton 
X-100) as indicated. Following washing, bound antibodies were detected by
Alexa 488 conjugated goat anti-rabbit (Molecular Probes) or goat antimouse
Cy3 (Sigma) secondary antibodies. To stain the nuclei, tissue sections were
incubated with 4,6-diamidino-2-phenylindole (DAPI, Sigma) and slides
were mounted in Fluoromount G (Biozol, Eching, Germany). Evaluation was
performed by fluorescence microscopy (Keyence).
FACS analysis
Human podocytes were left untreated or treated for 48 hrs with 100 g/ml
oxLDL. Cells were trypsinized and washed twice with PBS. To investi-
gate 3-integrin expression, cells were incubated for 30 min. with the
monoclonal antibody against 3-integrin (Chemicon) followed by FITC-
conjugated antimouse secondary antibody. After washing twice in PBS,
stained cells were analysed with an FACS cell analyser (Becton Dickinson,
Heidelberg, Germany) using Cellquest Software (Becton Dickinson).
Immunohistochemistry
Paraffin tissue sections were deparaffinized in xylene, rehydrated through
a graded ethanol series and washed in 10 mM phosphate-buffered 150 mM
saline, pH 7.4. Antigen retrieval was performed by incubating the tissue
sections for 20 min. in 0.01 M sodium citrate buffer, pH 6.0, in a
microwave oven (500 W). Tissue sections were treated with 3% H2O2 in
methanol for 30 min. at room temperature. After blocking the sections with
PBS containing 10% horse serum, 1% BSA for 1 hr, the sections were
incubated with an Avidin/Biotin Blocking Kit (Linaris, Wertheim, Germany)
following the manufacturer protocol. The tissue sections were incubated
overnight at 4C with primary antibodies as indicated. After washing the
slides, the Universal Quick Kit (Linaris) was used to stain the kidney sec-
tions. As a substrate the AEC Substrate Kit from Biozol was used to detect
the immune complexes. Slides were counterstained with haematoxylin
(Roth, Karlsruhe, Germany). The sections were inspected with a digital
microscope from the company Keyence.
Immunofluorescence analysis on tissue sections
Paraffin tissue sections were deparaffinized in xylene, rehydrated through a
graded ethanol series and washed in 10 mM phosphate-buffered 150 mM
saline, pH 7.4. Antigen retrieval was performed by incubating the tissue sec-
tions for 20 min. in 0.01 M sodium citrate buffer, pH 6.0, in a microwave
oven (500 W). After incubation with blocking buffer (0.1% Triton X-100/ PBS
containing 1% BSA and 10% horse serum) for 1 hr, tissue sections were
incubated with the first antibodies (diluted in 1% BSA/10% horse
serum/PBS/0.1% Triton X-100) as indicated. Following washing, bound anti-
bodies were detected by Alexa 488 conjugated goat antimouse (Molecular
Probes) or goat anti-rabbit Cy3 (Molecular Probes) secondary antibodies.
Nuclei were stained with 4,6-diamidino-2-phenylindole (DAPI, Sigma) and
slides were mounted in Fluoromount G (Biozol, Eching, Germany).
Evaluation was performed by fluorescence microscopy (Keyence).
Uptake of DiI-labelled oxidized human LDL 
in podocytes and primary tubular cells
To analyse the uptake of DiI-labelled oxidized human LDL in human
podocytes and primary tubular cells, cells were grown on cover slips and
pre-incubated for 1 hr either with 10 g/ml IgG isotype control antibody
(R&D Systems), 10 g/ml CXCL16 blocking antibody (R&D Systems), or
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5 g/ml CD36 antibody (Abcam). Afterwards, 10 g/ml DiI-oxLDL was
added for 4 hrs to the cells, then media were gently removed from cells and
cells were washed three to four times with serum-free media. Subsequently,
cells were fixed with methanol/ 0.01% EDTA for 20 min. at –20C, nuclei
were stained with 4,6-diamidino-2-phenylindole (DAPI, Sigma) and slides
were mounted in Fluoromount G (Biozol) and analysed with fluorescence
microscopy (Keyence).
Animals
Type 1 diabetes mellitus was induced in 2-month-old male C57BL/6 mice
(Charles River Laboratories, Sulzfeld, Germany) by three consecutively
daily intraperitoneal injections of streptozotocin (Sigma) (45 mg per kg of
body weight) dissolved in 100 mmol/l sodium citrate buffer (pH 4.5).
Control animals were injected only with citrate buffer. Mice that developed
glucosuria received a subcutaneous insulin implant (Linplant) (Linshin,
Ontario, Canada) to prevent ketoacidosis. Blood glucose concentrations
were measured before the induction of diabetes and thereafter at 10-day
intervals (Accu-Chek Sensor, Roche Diagnostics, Mannheim, Germany).
Monitoring of diabetes was performed as described [34]. Kidneys (n 	
5 per group) were harvested at day 5, 10, 17, 19, 30, 40 and 50 days after
induction of diabetes. All animal experimentation was conducted in accor-
dance with the German Animal Protection Act and had been approved by
the Ethics Review Committee for laboratory animals of the District
Government of Darmstadt, Germany.
Statistical analysis
Data were analysed by unpaired two-tailed t-test or one-way ANOVA with
Tukey- Kramer test for multiple comparisons using Graph Pad Instsat-2. A
P-value of less than 0.05 was considered to show a significant difference
between two groups.
Results
CXCL16 and CD36 function as scavenger recep-
tors for oxLDL in human podocytes and primary
tubular cells
Until now, very few data exist about the expression of oxLDL scav-
enger receptors in the kidney. Constitutive expression of CD36
[35] and CXCL16 [36] has been described in tubular epithelia of
the human kidney. In addition, our group has recently described
that CXCL16 is expressed in human podocytes (Gutwein et al.,
unpublished data). To analyse the receptors which mediate oxLDL
uptake in podocytes and primary tubular cells, experiments with
blocking antibodies were performed. The application of a CXCL16
specific blocking antibody strongly reduced the amount of DiI-
oxLDL uptake in human podocytes (Fig. 1A and B). In addition,
blocking CD36 receptor function reduced the uptake of DiI-oxLDL
but to a much lesser extent (Fig. 1A and B). Blocking of both
receptors (CXCL16 and CD36) inhibited the uptake of oxLDL in
human podocytes to a similar extent than CXCL16 alone (Fig. 1A and
B). In contrast to podocytes, the uptake of oxLDL in tubular cells was
mainly mediated via CD36 and only partially involved CXCL16 
(Fig. 1C and D). Again, combined blocking of CXCL16 and CD36
inhibited the uptake of oxLDL to a similar extent than CD36 alone
(Fig. 1C and D). Weak expression of CD36 in human podocytes was
determined by confocal immunofluorescence analysis (Fig. 1E). In
contrast to CD36, stronger constitutive CXCL16 expression was
detectable in human podocytes (Fig. 1F). Taken this data together, in
podocytes CXCL16 mediates mainly the uptake of oxLDL, whereas in
tubular cells CD36 seems to be the main receptor for oxLDL.
CXCL16 mediated uptake of oxLDL induced the
production of ROS and fibronectin in podocytes
and reduced the 3 integrin expression
It has been recently shown that alterations in the signalling cas-
cades and the hence ensuing morphological changes in podocytes
are mainly responsible for the development of proteinuria [37, 38].
To investigate the influence of oxLDL uptake on the morphology of
human podocytes we analysed the expression of the cytoskeleton
protein F-actin by phalloidin staining. As shown in Fig. 2A, oxLDL
induced morphological changes of podocytes which was accom-
panied by the reduction of F-actin stress fibres. These effects were
almost completely blocked by using a CXCL16 blocking antibody.
Application of the CD36 antibody only partially reduced the effect
of oxLDL on podocytes morphology (Fig. 2A). The combined
treatment with CXCL16 and CD36 blocking antibodies had no
additional influence on the F-actin expression in comparison to the
CXCL16 blocking antibody alone (Fig. 2A). In addition, the treat-
ment of human podocytes with TGF- resulted in a strong reduc-
tion of F-actin stress fibers (Fig. 2A).
One main receptor attaching podocytes to the glomerular base-
ment membrane is the integrin 31 [39]. As documented in Fig. 2B
application of oxLDL down-regulated 3-integrin expression.
Importantly, blocking surface-expressed CXCL16 significantly
restored the expression of 3-integrin (Fig. 2B). In addition the
treatment with a CD36 specific blocking antibody led to a recovery
of the 3-integrin expression. The most prominent influence on the
3-integrin expression was observed by the combined treatment
with a CXCL16 and CD36 antibody (Fig. 2B). Similar to oxLDL
treatment the application of TGF- also reduced 3-integrin
expression (Fig. 2B). To quantify the effect of oxLDL on 3-integrin
expression, we performed FACS analysis of human podocytes 
48 hrs after oxLDL treatment. OxLDL led to a 15% reduction of 
3-integrin surface expression (Fig. 2C). In addition, confocal
  fluorescence analysis revealed, that oxLDL treatment reduced 3-
integrin expression at focal contacts, which could be restored by
CXCL16 blocking antibody treatment (data not shown).
It is known that increased production of extracellular matrix
from podocytes is a hallmark in DN [40]. Therefore the effect of
oxLDL mediated uptake on fibronectin production was investigated.
© 2009 The Authors
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As demonstrated in Fig. 2D, oxLDL dramatically induced
fibronectin production in human podocytes. Blocking the uptake
of oxLDL with antibodies against CXCL16 or CD36 significantly
reduced the fibronectin production. Notably, the strongest
inhibitory effect was seen with CXCL16 blocking antibody and with
the combined treatment of CXCL16 and CD36 antibodies (Fig. 2D).
Again, TGF- known to induce fibronectin expression was used as
positive control.
Blocking of CXCL16 and CD36 reduced 
oxLDL-mediated ROS production
ROS have been identified as potential major contributors to the
pathogenesis of diabetic kidney disease [41]. To investigate the
role of oxLDL in ROS production in human podocytes, we
analysed the fluorescence intensity of ROS sensitive 5-(and-6)-
chloromethyl-27-dichlorodihydro-fluorescein diacetate after
oxLDL and TGF- treatment. As shown in Fig. 3, oxLDL signifi-
cantly induced ROS production in human podocytes. Importantly,
ROS production was significantly inhibited by pre-incubation of
podocytes with blocking antibody against CXCL16 (Fig. 3A and B).
In addition the oxLDL-induced ROS production was also signifi-
cantly inhibited by the blockage of CD36 (Fig. 3A and B).
Furthermore, TGF- strongly increased the amount of ROS in
human podocytes (Fig. 3A and B).
Down-regulation of ADAM10 under 
hyperglycaemic conditions is accompanied 
by the induction of CXCL16 in human podocytes
Hyperglycaemia is an important determinant in the pathogenesis
of diabetic microvascular complications in both type 1 and type 2
diabetes [42]. To analyse the influence of hyperglycaemia on the
expression of CXCL16 and ADAM10, human podocytes were
  cultured in LG (	5 mM) or HG (	30 mM) containing media. As
documented in Fig. 4A and B, HG treatment led to a significant
induction of cellular CXCL16 in human podocytes 24 and 120 hrs
after treatment. Importantly we also noticed a down-regulation of
ADAM10 expression after HG treatment at both time-points (Fig. 4A,
B and C). In addition, with a CXCL16 specific ELISA we confirmed
that hyperglycaemic conditions increased cellular CXCL16 expres-
sion (Fig. 4D). To investigate if HG levels induce CXCL16 mRNA
expression in podocytes, we performed real-time PCR. As shown
in Fig. 4E, treatment of podocytes for 24 and 72 hrs with HG con-
taining media significantly induced CXCL16 mRNA. Furthermore,
we provide evidence that hyperglycaemic conditions reduces the
release of CXCL16 from podocytes (Fig. 4F). To investigate, if the
down-regulation of ADAM10 is involved in the reduced shedding
of CXCL16 we performed siRNA experiments against ADAM10. As
documented in Fig. 4G, blocking ADAM10 protein synthesis
increased cellular CXCL16 and reduced the constitutive cleavage
of CXCL16 (Fig. 4H).
CXCL16 and oxLDL expression is induced 
in podocytes and tubular cells of streptozotocin
treated mice
Decreased number in podocytes, broadening of the foot
processes, and reduction of nephrin expression has been reported
in animal models of type 1 diabetes [43, 44]. To investigate the
expression of CXCL16 in a STZ-induced mouse model of type 1
diabetes, we performed immunohistochemical analysis of CXCL16
in kidney sections of different time-points after induction. As
shown in Fig. 5A and B, 17 days after STZ treatment, CXCL16
expression was significantly induced in podocytes and tubular
cells. The glomerular CXCL16 expression increased over time and
showed the strongest induction 50 days after STZ injection 
© 2009 The Authors
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Fig. 1 Involvement of CXCL16 and CD36 in the uptake of oxLDL. (A) DiI-oxLDL uptake was analysed after the pre-treatment of podocytes with an IgG
control antibody (control), a CXCL16 blocking antibody (C16 Ab), a CD36 blocking antibody (CD36 Ab), or both antibodies (C16 Ab  CD36 Ab).
After pre-incubation of human podocytes with the blocking antibodies, cells were incubated for 4 hrs with 100 g/ml DiI-oxLDL (red) and subsequently
washed with PBS and fixed in methanol/0.02% EDTA. In addition, cells were stained with DAPI to visualize the nuclei (blue). (B) Semi-quantitative analy-
sis of the fluorescence intensity of DiI-oxLDL in cells pre-treated with a control IgG antibody (control), a CXCL16 antibody (C16 Ab), a CD36 antibody
(CD36Ab) or with a combination of both antibodies (C16ABCD36Ab). Mean fluorescence of DiI-oxLDL was measured with an image software from
Keyence. (C) DiI-oxLDL uptake was analysed after pre-incubation of the primary tubular cell line HRCEpiC with an IgG control antibody (control), a
CXCL16 blocking antibody (C16Ab), a CD36 blocking antibody (CD36Ab) or the combination of both blocking antibodies (C16AbCD36Ab) and
visualized by immunofluorescence microscopy. After pre-incubation of HRCEpiC with the different blocking antibodies, cells were incubated for 4 hrs
with 100 g/ml DiI-oxLDL (red) and subsequently washed with PBS and fixed in methanol/0.02% EDTA. The cells were stained with DAPI to visualize
the nuclei (blue). (D) Fluorescence intensity of DiI-oxLDL in HRCEpiC pre-treated with an IgG control antibody (control), a CXCL16 antibody (C16 Ab),
a CD36 antibody (CD36Ab) or the combination of both antibodies (C16AbCD36Ab) was determined with the BZ-Analyzer software (Keyence). Data
represent mean  S.D. ***P 
 0.001; **P 
 0.01 considered statistically significant compared to the control. (E) Podocytes were fixed with 4%
paraformaldehyde and CD36 expression was investigated using monoclonal CD36 and Cy3 coupled secondary antibodies (red). The cells were stained
with DAPI to detect the nuclei (blue) of the cells. Fluorescence analyses were performed with a LSM 510 Meta confocal laser-scanning microscope 
(Carl Zeiss, Jena, Germany). (F) Podocytes were fixed with methanol and incubated with CXCL16 antibodies followed by Alexa 488 coupled secondary
antibodies (green). Cells were than incubated with DAPI to visualize nuclei (blue). Fluorescence analyses were performed with a LSM 510 Meta confo-
cal laser-scanning microscope (Carl Zeiss). J. Cell. Mol. Med. Vol 13, No 9B, 2009
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mouse kidney sections revealed that oxLDL expression was also
induced in STZ-treated mice (Fig. 5C). Notably, no oxLDL expres-
sion could be seen in kidneys of control mice (Fig. 5C).
In biopsies of patients with DN increased
glomerular CXCL16 was accompanied by high
levels of oxLDL
To further investigate the expression of CXCL16, ADAM10 and
oxLDL in kidney sections of patients we DN, we performed
immunofluorescence analysis. As documented in Fig. 6 increased
CXCL16 expression was mainly found in podocytes (Fig. 6B).
Interestingly, increased glomerular CXCL16 expression was
accompanied with lower levels of ADAM10 (Fig. 6A and B). In con-
trast, the amount of ADAM10 in tubuli was not significantly
changed between normal kidneys and patients with DN (Fig. 6A).
In addition in glomeruli and tubuli of kidney biopsies of patients
with DN increased levels of oxLDL were detectable (Fig. 6C and D).
To investigate if CXCL16 may be responsible for oxLDL accumula-
tion in glomeruli of DN patients, we performed double immunoflu-
orescense analysis of CXCL16 and oxLDL in biopsies of DN
patients. Importantly, co-localization of CXCL16 and oxLDL 
(Fig. 6E, yellow colour) was observed in glomeruli of DN patients,
assuming that CXCL16 represents a scavenger receptor for oxLDL
also in vivo.
Discussion
DN is the leading cause of end-stage renal failure and is clinically
characterized by proteinuria und progressive renal insufficiency
[45]. Several interventions have been shown to slow down the
progression of DN, but unfortunately they cannot prevent the dis-
ease [46]. Improved therapeutic treatment of DN is urgently
needed but is hampered due to the incomplete understanding of
the complex mechanism of the disease. In this context podocytes
seem to be an attractive target of research. It is commonly
3816 © 2009 The Authors
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Fig. 2 Role of CXCL16 and CD36 in the oxLDL-induced regulation of F-actin, 3-integrin and fibronectin expression in human podocytes.
Immunofluorescence analyses of F-Actin stress fibers (A), 3-integrin (B) and fibronectin expression (D) in human podocytes 48 hrs after oxLDL (100
g/ml) treatment in the presence of 10 g/ml IgG control antibody (control/ oxLDL), 10 g/ml CXCL16 blocking antibody (oxLDLC16Ab), 5 g/ml
CD36 blocking antibody (oxLDLCD36Ab) or the combination of both antibodies (oxLDLC16AbCD36Ab). Treated human podocytes grown on cover
slips were fixed with 4% paraformaldehyde/PBS solution and blocked with 1% bovine serum albumin/0.2 Triton-X-100/PBS. The cells were stained with
DAPI to visualize the nuclei, with Alexa 594 conjugated Phalloidin to visualize the F-actin stress fibers (red fluorescence) and with an Alexa 488 coupled
secondary antibodies to visualize 3-integrin (green) and fibronectin (green). (C) 3-integrin surface expression was investigated by FACS analysis 48 hrs
after the treatment of podocytes with 100 g/ml oxLDL. Black line shows 3-integrin expression of untreated podocytes, whereas the red line repre-
sents the surface expression of 3-integrin after oxLDL treatment. Mean fluorescence of 3-integrin expression of untreated (control) and oxLDL treated
podocytes is depicted in a graph.J. Cell. Mol. Med. Vol 13, No 9B, 2009
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accepted that podocytes are an early target of injury in the onset
of DN and therefore may be the major culprit of the disease.
Interestingly a link between oxLDL and the injury of podocytes has
been already described [10]. In contrast the scavenger receptors
responsible for the uptake of oxidized LDL in podocytes have been
so far not characterized. We have recently shown that human
podocytes constitutively express the scavenger receptor CXCL16
(Gutwein et al., unpublished data). Notably in our current study we
identified CXCL16 and CD36 as the main receptors for the uptake
of oxLDL in podocytes and in tubular cells respectively.
It is well accepted that the number of podocytes is reduced in
animal models of DN [47] and in biopsies of patients with early
and late DN [20, 21]. The exact aetiology for the reduction in the
number of podocytes in diabetes remains speculative, but two
mechanisms have been suggested: apoptosis and cell detach-
ment. It has been recently shown that oxLDL is able to induce
apoptosis in murine podocytes [10]. In contrast in our study
oxLDL did not lead to apoptosis in human podocytes. The effects
induced by oxLDL can differ due to the kind of LDL, its degree of
oxidative modification, the amount of oxLDL and on the type of
target cell involved [48]. The discrepancy in the above mentioned
study and our observations could be explained by an increased
sensitivity of mouse podocytes to the cytotoxicity of oxLDL.
Furthermore strongly oxidized LDL often exerts a cytotoxic effect,
whereas minimally oxidized LDL causes more subtle alteration in
vascular cell functions [48]. Currently, we investigate the effects of
© 2009 The Authors
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Fig. 3 Blocking antibodies against CXCL16 and CD36 inhibit oxLDL-
induced ROS production in human podocytes. (A) Human podocytes
grown on cover slips were incubated with serum free media or with 
100 g/ml oxLDL (oxLDL) for 1 hr either in the presence of an IgG con-
trol antibody (control/oxLDL), a CXCL16 blocking antibody (10 g/ml)
(oxLDLC16 Ab), a CD36 antibody (5 g/ml) (oxLDLCD36 Ab), a
CXCL16 (10 g/ml) and a CD36 (5 g/ml) blocking antibody
(oxLDLC16 AbCD36 Ab) or stimulated with TGF- (10 ng/ml). Cells
were washed with Dulbecco’s PBS and incubated in the dark for 20 min.
with 5 mM 5-(and-6)-chloromethyl-27-dichlorodihydrofluorescein diac-
etate (green fluorescence). (B) Semi-quantitative analysis of fluorescence
intensities of ROS production in human podocytes (control) treated with
oxLDL in the presence of an IgG antibody (oxLDL), a CXCL16 blocking
antibody (oxLDLC16 Ab), a CD36 blocking antibody (oxLDLCD36 Ab)
or both blocking antibodies (oxLDLC16 AbCD36 Ab), or treated with
TGF- using the BZ-Analyzer software (Keyence). Data represent mean 
S.D. ***P 





 0.05 considered statistically significant com-
pared to oxLDL/IgG control antibody treated cells.3818 © 2009 The Authors
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Fig. 4 Effect of HG on cellular CXCL16 and ADAM10 expression in human
podocytes. (A) Immunofluorescence staining of CXCL16 and ADAM10
expression in human podocytes treated for 24 or 
120 hrs with LG (5 mM) or HG (30 mM) containing media. The cells were
stained with DAPI to visualize nuclei (blue), and with Alexa Fluor 488 and
Cy3 coupled secondary antibodies to visualize the distribution of ADAM10
(green) and CXCL16 (red) proteins. (B) Immunofluorescence results of
CXCL16 and ADAM10 expression after 24 hrs glucose treatment using the





 0.01 considered statistically significant compared to cells
treated with LG concentration. (C) Podocytes were incubated 72 hrs with
5 or 30 mM glucose containing media. Cells were than lysed and ADAM10
expression was determined by Western blot analysis. 
-actin was used to demonstrate equal sample loading. (D) CXCL16 pro-
tein expression was measured with a CXCL16 specific ELISA 24 hrs after
the treatment of podocytes with 5 mM glucose or 30 mM glucose. Data
represent mean  S.D. ***P 
 0.001, 
**P 
 0.01 considered statistically
significant compared to cells treated with LG containing media. (E) mRNA
from podocytes was isolated at times indicated, transcribed in the cDNA
as described in material and methods and real-time PCR was performed.
(F) Release of CXCL16 was measured in podocytes incubated for 24, 72
or 120 hrs with LG (5 mM) or HG (30 mM) containing media.
Supernatants were prepared as described in material and methods and
soluble CXCL16 was measured by CXCL16 specific ELISA. 
(G-I) ADAM10 expression was down-regulated in human podocytes by
ADAM10 specific siRNA (controlled by ADAM10 western blot, depicted
above the graph) and   cellular (G) and soluble CXCL16 (I) was measured
by a CXCL16 specific ELISA. A10 	 ADAM10, sc 	 scrambled.3820 © 2009 The Authors
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different forms of oxLDL on cellular responses like survival and
proliferation in human podocytes.
Although we did not find in our study any cytotoxic effects of
oxLDL in human podocytes, we noticed other important proper-
ties of oxLDL in human podocytes. Firstly, we demonstrated that
oxLDL led to a down-regulation of 3-integrin, which could be
efficiently blocked by pre-incubation with a CXCL16 blocking
antibody. 31 is known to be a principal protein involved in
attaching podocytes to the glomerular basement membrane.
Interestingly, altered expression of 31 has been detected in
podocytes of patients with DN [49]. Therefore down-regulation of
31 could lead to the detachment of podocytes, one possible
explanation for the decreased number of podocytes found in
patients and animal models of DN. In the same line it has been
reported that the loss of podocytes in the urine has been associ-
ated with the progression of DN. When we investigated patholog-
ical factors, which are known to play important role in the devel-
opment and progression of DN, we found that TNF- (Gutwein 
et al., unpublished data) and hyperglycaemic conditions induced
CXCL16 expression in human podocytes. Strikingly, HG contain-
ing media induced CXCL16 expression but reduced ADAM10
expression in human podocytes. In addition also in patients with
DN glomerular ADAM10 expression was dramatically reduced. In
the same line, our study demonstrated that ADAM10 knockdown
experiments induced cellular CXCL16 and reduced the constitu-
tive cleavage of CXCL16 in human podocytes. In addition,
ADAM10 contribute to the processing of many other important
cytokines, growth factors, adhesion molecules [50] and it is able
to degrade collagen IV [51]. Therefore down-regulation of
ADAM10 in vivo could participate in the development of mem-
brane thickening, known to be a characteristic feature of DN [52].
In the same line, long-term incubation of podocytes with HG
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Fig. 5 CXCL16 and oxLDL expression is increased in streptozotocin-treated mice Immunohistochemical analysis of CXCL16 (A, B) and oxLDL (C)
expression in kidney sections of citrate buffer (control) or streptozotocin (STZ) -treated mice. Representative micrographs show CXCL16 expression in
renal glomeruli (A) and tubules (B) 5, 10, 17, 19, 30, 40 and 50 days after STZ injection (examples are marked by black arrows). (C) OxLDL expression
was monitored 17, 30, 40 and 50 days after induction of diabetes. Arrows mark oxLDL expressing renal cells.3822 © 2009 The Authors
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  containing media was shown to reduce the production of MMP-
9, one major metalloproteinase involved in the degradation of the
extracellular matrix. Furthermore our study presents another
important finding. Beside the morphological changes seen after
oxLDL treatment (as documented with F-actin immunofluores-
cence staining), CXCL16 mediated uptake of oxidized LDL
induced a dramatic up-regulation of fibronection production.
Again interfering with blocking CXCL16 antibodies significantly
reduced the fibronection overproduction, assuming an important
role of CXCL16 mediated uptake of oxLDL in the progression of
glomerular kidney diseases.
It has been postulated that localized tissue oxidative stress is a
key component in the development of DN [2]. Oxidative stress (or
oxidant-derived tissue injury) occurs when production of oxidants
or ROS exceeds local antioxidant capacity [2]. Importantly, over-
expression of the antioxidant metallothionein in podocytes
reduced the development of DN, highlighting the important role of
podocytes in the onset of DN [52]. Beside this our study presents
evidence that CXCL16 mediated uptake of oxLDL induced ROS
production in podocytes. In addition, it is known that hypergly-
caemic conditions can lead to ROS production in podocytes [53]
and together with increased CXCL16 expression it could lead to a
vicious circle which leads to high levels of ROS production in
glomeruli of diabetic patients. Combined treatment of antioxidants
and CXCL16 blocking antibodies may be a potential strategy to
inhibit the development of DN.
To investigate CXCL16 and oxLDL in DN in vivo we performed
immunohistochemical analysis on kidney sections of a STZ-
induced diabetic mouse model. Importantly, already 17 days after
STZ treatment a strong up-regulation of CXCL16, predominantly in
podocytes was observed. This elevated CXCL16 expression was
accompanied with increased oxLDL expression. Furthermore we
© 2009 The Authors
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Fig. 6 Expression of CXCL16 and ADAM10 in tissue section of normal kidney and patients with DN. (A) Renal tissue of normal kidney (normal) and of
patients diagnosed with DN were analysed with double immunofluorescence staining of CXCL16 (red fluorescence) and ADAM10 (green fluorescence)
in glomeruli (upper panel) and tubules (lower panel). (B) Semi-quantitative analysis of fluorescence intensities of glomerular CXCL16 (grey bars) and
glomerular and ADAM10 (black bars) expression is depicted in a graph. (C) oxLDL expression in renal sections of normal kidney (normal) and patients
diagnosed with DN. Tissue sections were stained with oxLDL antibody followed by Cy3 coupled secondary antibody (red). (D) Immunofluorescence
results of oxLDL expression in renal tissue of normal kidney and of patients with DN. Data represent mean  S.D. ***P 
 0.001, **P 
 0.01 consid-
ered statistically significant compared to the normal kidney. (E) Double immunofluorescense analysis of oxLDL (red colour) and CXCL16 (green colour)
was performed on kidney biopsies of patients with DN. Tissue section was stained with DAPI to visualize the nuclei of the cells.References
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